KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Receivables (2017 - 2023)

NovoCure (NVCR) has disclosed Change in Receivables for 7 consecutive years, with -$2.6 million as the latest value for Q3 2023.

  • Quarterly Change in Receivables rose 77.07% to -$2.6 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$20.3 million through Sep 2023, down 165.14% year-over-year, with the annual reading at -$2.5 million for FY2022, 51.67% up from the prior year.
  • Change in Receivables hit -$2.6 million in Q3 2023 for NovoCure, up from -$6.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $19.7 million in Q1 2020 to a low of -$14.5 million in Q1 2023.
  • Historically, Change in Receivables has averaged $1.8 million across 5 years, with a median of $2.0 million in 2019.
  • Biggest five-year swings in Change in Receivables: surged 868.47% in 2020 and later crashed 409.23% in 2022.
  • Year by year, Change in Receivables stood at $19.5 million in 2019, then crashed by 116.44% to -$3.2 million in 2020, then soared by 57.93% to -$1.3 million in 2021, then surged by 379.96% to $3.8 million in 2022, then crashed by 170.06% to -$2.6 million in 2023.
  • Business Quant data shows Change in Receivables for NVCR at -$2.6 million in Q3 2023, -$6.9 million in Q2 2023, and -$14.5 million in Q1 2023.